{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:51:43Z","timestamp":1785210703477,"version":"3.55.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.2169\/internalmedicine.3813-19","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T22:15:31Z","timestamp":1585692931000},"page":"971-976","source":"Crossref","is-referenced-by-count":11,"title":["Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease"],"prefix":"10.2169","volume":"59","author":[{"given":"Yumi","family":"Aoyama","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Tokyo Women's Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekiko","family":"Taneda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"},{"name":"Clinical Research Division for Polycystic Kidney Disease, Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women's Medical University, Japan"},{"name":"Clinical Research Division for Polycystic Kidney Disease, Department of Nephrology, Tokyo Women's Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"1. Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney international 91: 284-293, 2017.","journal-title":"Kidney International","ISSN":"https:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749, 2001.","DOI":"10.1001\/jama.285.21.2743"},{"key":"3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"3. Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clinical and experimental nephrology 22: 843-849, 2018.","journal-title":"Journal of Clinical and Experimental Nephrology","ISSN":"https:\/\/id.crossref.org\/issn\/1342-1751","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946, 2002.","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Taneda S, Honda K, Nakajima I, Huchinoue S, Oda H. Renal transplantation between siblings with unrecognized Fabry disease. Transplantation proceedings 45: 115-118, 2013.","DOI":"10.1016\/j.transproceed.2012.10.024"},{"key":"6","unstructured":"6. Nakamichi T, Miyazaki M, Nakayama K, et al. Fabry's disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep 2: 49-52, 2013."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shimohata H, Maruyama H, Miyamoto Y, Takayasu M, Hirayama K, Kobayashi M. Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease. CEN Case Rep 6: 148-151, 2017.","DOI":"10.1007\/s13730-017-0262-5"},{"key":"8","unstructured":"8. Matsuura H, Asano K. Mulberry bodies: Fabry disease. Am J Med. Forthcoming."},{"key":"9","unstructured":"9. Chong PF, Nakamura K, Kira R. Mulberries in the urine: a tell-tale sign of Fabry disease. J Inherit Metab Dis 41: 745-746, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Onishi R, Kanaoka K, Sugiura J, et al. A cardiac variant of Fabry disease diagnosed with chance urinary Mulberry cells. Intern Med 57: 3385-3388, 2018.","DOI":"10.2169\/internalmedicine.1177-18"},{"key":"11","unstructured":"11. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111, 2009."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20: 1132-1139, 2009.","DOI":"10.1681\/ASN.2008080870"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557, 2007.","DOI":"10.1681\/ASN.2006080816"},{"key":"14","unstructured":"14. Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27: 1042-1049, 2012."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52: 353-358, 2015.","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"16","unstructured":"16. Utsumi K, Mitsuhashi F, Asahi K, et al. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments. Clin Chim Acta 360: 103-107, 2005."},{"key":"17","unstructured":"17. Selvarajah M, Nicholls K, Hewitson TD, Becker GJ. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique. Nephrol Dial Transplant 26: 3195-3202, 2011."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Murayama Y, Uchida M, Tojo A, Ishimitsu T. Electron microscopy of urinary sediments in Fabry disease. Kidney Int 94: 834, 2018.","DOI":"10.1016\/j.kint.2018.04.010"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Skrunes R, Tondel C, Leh S, et al. Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease. Clin J Am Soc Nephrol 12: 1470-1479, 2017.","DOI":"10.2215\/CJN.01820217"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/7\/59_3813-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T03:51:44Z","timestamp":1585972304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/7\/59_3813-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3813-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}